nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—PPP3CA—pons—amyotrophic lateral sclerosis	0.0266	0.138	CbGeAlD
Tacrolimus—Skin candida—Riluzole—amyotrophic lateral sclerosis	0.0231	0.0409	CcSEcCtD
Tacrolimus—MTOR—forelimb—amyotrophic lateral sclerosis	0.0186	0.0969	CbGeAlD
Tacrolimus—MTOR—hindlimb—amyotrophic lateral sclerosis	0.0168	0.0871	CbGeAlD
Tacrolimus—MTOR—appendage—amyotrophic lateral sclerosis	0.0144	0.0748	CbGeAlD
Tacrolimus—Peritonitis—Riluzole—amyotrophic lateral sclerosis	0.0105	0.0187	CcSEcCtD
Tacrolimus—PPP3CA—hindbrain—amyotrophic lateral sclerosis	0.0103	0.0537	CbGeAlD
Tacrolimus—MTOR—hindbrain—amyotrophic lateral sclerosis	0.00764	0.0397	CbGeAlD
Tacrolimus—Uterine haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00762	0.0135	CcSEcCtD
Tacrolimus—Hemiplegia—Riluzole—amyotrophic lateral sclerosis	0.00745	0.0132	CcSEcCtD
Tacrolimus—Disseminated intravascular coagulation—Riluzole—amyotrophic lateral sclerosis	0.00745	0.0132	CcSEcCtD
Tacrolimus—Dental caries—Riluzole—amyotrophic lateral sclerosis	0.00714	0.0127	CcSEcCtD
Tacrolimus—Hypochromic anaemia—Riluzole—amyotrophic lateral sclerosis	0.00686	0.0122	CcSEcCtD
Tacrolimus—Fungal skin infection—Riluzole—amyotrophic lateral sclerosis	0.00637	0.0113	CcSEcCtD
Tacrolimus—Furunculosis—Riluzole—amyotrophic lateral sclerosis	0.00626	0.0111	CcSEcCtD
Tacrolimus—ABCA5—medulla oblongata—amyotrophic lateral sclerosis	0.00612	0.0318	CbGeAlD
Tacrolimus—PPP3CA—brainstem—amyotrophic lateral sclerosis	0.00593	0.0308	CbGeAlD
Tacrolimus—Thrombocytopenic purpura—Riluzole—amyotrophic lateral sclerosis	0.00567	0.0101	CcSEcCtD
Tacrolimus—Hernia—Riluzole—amyotrophic lateral sclerosis	0.00567	0.0101	CcSEcCtD
Tacrolimus—Cerebral ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00551	0.00975	CcSEcCtD
Tacrolimus—ABCA5—spinal cord—amyotrophic lateral sclerosis	0.00546	0.0283	CbGeAlD
Tacrolimus—Peripheral vascular disorder—Riluzole—amyotrophic lateral sclerosis	0.00543	0.00961	CcSEcCtD
Tacrolimus—Furuncle—Riluzole—amyotrophic lateral sclerosis	0.00543	0.00961	CcSEcCtD
Tacrolimus—Pneumothorax—Riluzole—amyotrophic lateral sclerosis	0.00535	0.00947	CcSEcCtD
Tacrolimus—Vaginal moniliasis—Riluzole—amyotrophic lateral sclerosis	0.00527	0.00934	CcSEcCtD
Tacrolimus—Vulvovaginal candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00506	0.00896	CcSEcCtD
Tacrolimus—Vulvovaginal mycotic infection—Riluzole—amyotrophic lateral sclerosis	0.00487	0.00862	CcSEcCtD
Tacrolimus—Cerebral haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00481	0.00851	CcSEcCtD
Tacrolimus—MTOR—embryo—amyotrophic lateral sclerosis	0.00478	0.0248	CbGeAlD
Tacrolimus—Osteoporosis—Riluzole—amyotrophic lateral sclerosis	0.00475	0.00841	CcSEcCtD
Tacrolimus—ABCA5—nervous system—amyotrophic lateral sclerosis	0.0046	0.0239	CbGeAlD
Tacrolimus—Gastric ulcer—Riluzole—amyotrophic lateral sclerosis	0.00458	0.00811	CcSEcCtD
Tacrolimus—Generalised oedema—Riluzole—amyotrophic lateral sclerosis	0.00447	0.00792	CcSEcCtD
Tacrolimus—ABCA5—central nervous system—amyotrophic lateral sclerosis	0.00443	0.023	CbGeAlD
Tacrolimus—Myoclonus—Riluzole—amyotrophic lateral sclerosis	0.00442	0.00783	CcSEcCtD
Tacrolimus—Enlargement abdomen—Riluzole—amyotrophic lateral sclerosis	0.00442	0.00783	CcSEcCtD
Tacrolimus—MTOR—brainstem—amyotrophic lateral sclerosis	0.00438	0.0227	CbGeAlD
Tacrolimus—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00437	0.00775	CcSEcCtD
Tacrolimus—ABCA5—cerebellum—amyotrophic lateral sclerosis	0.00433	0.0225	CbGeAlD
Tacrolimus—Blepharitis—Riluzole—amyotrophic lateral sclerosis	0.00433	0.00766	CcSEcCtD
Tacrolimus—Myasthenia—Riluzole—amyotrophic lateral sclerosis	0.00423	0.0075	CcSEcCtD
Tacrolimus—Respiratory distress—Riluzole—amyotrophic lateral sclerosis	0.00419	0.00742	CcSEcCtD
Tacrolimus—Oral candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00419	0.00742	CcSEcCtD
Tacrolimus—PPP3CA—medulla oblongata—amyotrophic lateral sclerosis	0.00413	0.0215	CbGeAlD
Tacrolimus—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.0041	0.00727	CcSEcCtD
Tacrolimus—Supraventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00406	0.00719	CcSEcCtD
Tacrolimus—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00398	0.00705	CcSEcCtD
Tacrolimus—Seborrhoeic dermatitis—Riluzole—amyotrophic lateral sclerosis	0.0039	0.00691	CcSEcCtD
Tacrolimus—Intestinal obstruction—Riluzole—amyotrophic lateral sclerosis	0.0039	0.00691	CcSEcCtD
Tacrolimus—Hypercalcaemia—Riluzole—amyotrophic lateral sclerosis	0.00383	0.00678	CcSEcCtD
Tacrolimus—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.00376	0.00666	CcSEcCtD
Tacrolimus—Lung disorder—Riluzole—amyotrophic lateral sclerosis	0.00376	0.00666	CcSEcCtD
Tacrolimus—Ileus—Riluzole—amyotrophic lateral sclerosis	0.00376	0.00666	CcSEcCtD
Tacrolimus—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.00376	0.00666	CcSEcCtD
Tacrolimus—Laryngitis—Riluzole—amyotrophic lateral sclerosis	0.00369	0.00654	CcSEcCtD
Tacrolimus—PPP3CA—spinal cord—amyotrophic lateral sclerosis	0.00369	0.0191	CbGeAlD
Tacrolimus—Stupor—Riluzole—amyotrophic lateral sclerosis	0.00356	0.00631	CcSEcCtD
Tacrolimus—Pulmonary function test decreased—Riluzole—amyotrophic lateral sclerosis	0.00353	0.00626	CcSEcCtD
Tacrolimus—Respiratory depression—Riluzole—amyotrophic lateral sclerosis	0.00353	0.00626	CcSEcCtD
Tacrolimus—ABCA5—brain—amyotrophic lateral sclerosis	0.00351	0.0183	CbGeAlD
Tacrolimus—Pleural effusion—Riluzole—amyotrophic lateral sclerosis	0.00347	0.00615	CcSEcCtD
Tacrolimus—Ventricular fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00347	0.00615	CcSEcCtD
Tacrolimus—Amblyopia—Riluzole—amyotrophic lateral sclerosis	0.00345	0.0061	CcSEcCtD
Tacrolimus—Skin ulcer—Riluzole—amyotrophic lateral sclerosis	0.00342	0.00605	CcSEcCtD
Tacrolimus—Abscess—Riluzole—amyotrophic lateral sclerosis	0.00336	0.00596	CcSEcCtD
Tacrolimus—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00331	0.00586	CcSEcCtD
Tacrolimus—Glycosuria—Riluzole—amyotrophic lateral sclerosis	0.00328	0.00582	CcSEcCtD
Tacrolimus—Gamma-glutamyltransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00323	0.00573	CcSEcCtD
Tacrolimus—Endocrine disorder—Riluzole—amyotrophic lateral sclerosis	0.00321	0.00569	CcSEcCtD
Tacrolimus—Liver injury—Riluzole—amyotrophic lateral sclerosis	0.00316	0.0056	CcSEcCtD
Tacrolimus—PPP3CA—nervous system—amyotrophic lateral sclerosis	0.00311	0.0161	CbGeAlD
Tacrolimus—Delirium—Riluzole—amyotrophic lateral sclerosis	0.00309	0.00548	CcSEcCtD
Tacrolimus—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.00301	0.00533	CcSEcCtD
Tacrolimus—PPP3CA—central nervous system—amyotrophic lateral sclerosis	0.00299	0.0155	CbGeAlD
Tacrolimus—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.00295	0.00522	CcSEcCtD
Tacrolimus—Ventricular extrasystoles—Riluzole—amyotrophic lateral sclerosis	0.00295	0.00522	CcSEcCtD
Tacrolimus—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00293	0.00518	CcSEcCtD
Tacrolimus—Arthropathy—Riluzole—amyotrophic lateral sclerosis	0.00293	0.00518	CcSEcCtD
Tacrolimus—PPP3CA—cerebellum—amyotrophic lateral sclerosis	0.00292	0.0152	CbGeAlD
Tacrolimus—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.00291	0.00515	CcSEcCtD
Tacrolimus—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.00291	0.00515	CcSEcCtD
Tacrolimus—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.00287	0.00508	CcSEcCtD
Tacrolimus—Gout—Riluzole—amyotrophic lateral sclerosis	0.00285	0.00505	CcSEcCtD
Tacrolimus—Leukocytosis—Riluzole—amyotrophic lateral sclerosis	0.00283	0.00501	CcSEcCtD
Tacrolimus—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.00281	0.00498	CcSEcCtD
Tacrolimus—Ulcer—Riluzole—amyotrophic lateral sclerosis	0.00281	0.00498	CcSEcCtD
Tacrolimus—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.00281	0.00498	CcSEcCtD
Tacrolimus—Cataract—Riluzole—amyotrophic lateral sclerosis	0.0028	0.00495	CcSEcCtD
Tacrolimus—FKBP1A—medulla oblongata—amyotrophic lateral sclerosis	0.00275	0.0143	CbGeAlD
Tacrolimus—MTOR—spinal cord—amyotrophic lateral sclerosis	0.00272	0.0141	CbGeAlD
Tacrolimus—Respiratory failure—Riluzole—amyotrophic lateral sclerosis	0.00271	0.0048	CcSEcCtD
Tacrolimus—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00271	0.0048	CcSEcCtD
Tacrolimus—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00269	0.00477	CcSEcCtD
Tacrolimus—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.00266	0.00471	CcSEcCtD
Tacrolimus—Hepatocellular injury—Riluzole—amyotrophic lateral sclerosis	0.00266	0.00471	CcSEcCtD
Tacrolimus—Phosphatase alkaline increased—Riluzole—amyotrophic lateral sclerosis	0.00266	0.00471	CcSEcCtD
Tacrolimus—Dermatitis contact—Riluzole—amyotrophic lateral sclerosis	0.00263	0.00466	CcSEcCtD
Tacrolimus—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.00263	0.00466	CcSEcCtD
Tacrolimus—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00257	0.00455	CcSEcCtD
Tacrolimus—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00257	0.00455	CcSEcCtD
Tacrolimus—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00254	0.0045	CcSEcCtD
Tacrolimus—Fluid retention—Riluzole—amyotrophic lateral sclerosis	0.00253	0.00447	CcSEcCtD
Tacrolimus—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.0025	0.00442	CcSEcCtD
Tacrolimus—FKBP1A—spinal cord—amyotrophic lateral sclerosis	0.00245	0.0127	CbGeAlD
Tacrolimus—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.00244	0.00433	CcSEcCtD
Tacrolimus—Coma—Riluzole—amyotrophic lateral sclerosis	0.00243	0.00431	CcSEcCtD
Tacrolimus—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00241	0.00426	CcSEcCtD
Tacrolimus—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.00241	0.00426	CcSEcCtD
Tacrolimus—PPP3CA—brain—amyotrophic lateral sclerosis	0.00237	0.0123	CbGeAlD
Tacrolimus—Pulmonary oedema—Riluzole—amyotrophic lateral sclerosis	0.00237	0.0042	CcSEcCtD
Tacrolimus—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.00233	0.00413	CcSEcCtD
Tacrolimus—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.00231	0.00409	CcSEcCtD
Tacrolimus—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.00231	0.00409	CcSEcCtD
Tacrolimus—MTOR—nervous system—amyotrophic lateral sclerosis	0.00229	0.0119	CbGeAlD
Tacrolimus—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.00226	0.00401	CcSEcCtD
Tacrolimus—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00226	0.00401	CcSEcCtD
Tacrolimus—Phlebitis—Riluzole—amyotrophic lateral sclerosis	0.00224	0.00397	CcSEcCtD
Tacrolimus—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00222	0.00393	CcSEcCtD
Tacrolimus—Blood alkaline phosphatase increased—Riluzole—amyotrophic lateral sclerosis	0.00222	0.00393	CcSEcCtD
Tacrolimus—MTOR—central nervous system—amyotrophic lateral sclerosis	0.00221	0.0115	CbGeAlD
Tacrolimus—Photosensitivity—Riluzole—amyotrophic lateral sclerosis	0.0022	0.0039	CcSEcCtD
Tacrolimus—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00216	0.00382	CcSEcCtD
Tacrolimus—MTOR—cerebellum—amyotrophic lateral sclerosis	0.00216	0.0112	CbGeAlD
Tacrolimus—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00215	0.00381	CcSEcCtD
Tacrolimus—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00213	0.00377	CcSEcCtD
Tacrolimus—Injury—Riluzole—amyotrophic lateral sclerosis	0.0021	0.00372	CcSEcCtD
Tacrolimus—FKBP1A—nervous system—amyotrophic lateral sclerosis	0.00206	0.0107	CbGeAlD
Tacrolimus—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00206	0.00364	CcSEcCtD
Tacrolimus—Amnesia—Riluzole—amyotrophic lateral sclerosis	0.00206	0.00364	CcSEcCtD
Tacrolimus—Dermatitis exfoliative—Riluzole—amyotrophic lateral sclerosis	0.00205	0.00363	CcSEcCtD
Tacrolimus—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.00204	0.00361	CcSEcCtD
Tacrolimus—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00203	0.00359	CcSEcCtD
Tacrolimus—Anaphylactoid reaction—Riluzole—amyotrophic lateral sclerosis	0.002	0.00353	CcSEcCtD
Tacrolimus—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00199	0.00352	CcSEcCtD
Tacrolimus—FKBP1A—central nervous system—amyotrophic lateral sclerosis	0.00199	0.0103	CbGeAlD
Tacrolimus—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.00198	0.00351	CcSEcCtD
Tacrolimus—FKBP1A—cerebellum—amyotrophic lateral sclerosis	0.00194	0.0101	CbGeAlD
Tacrolimus—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00194	0.00343	CcSEcCtD
Tacrolimus—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00342	CcSEcCtD
Tacrolimus—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00193	0.00342	CcSEcCtD
Tacrolimus—ORM1—spinal cord—amyotrophic lateral sclerosis	0.00192	0.00996	CbGeAlD
Tacrolimus—Migraine—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00337	CcSEcCtD
Tacrolimus—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00337	CcSEcCtD
Tacrolimus—Psychotic disorder—Riluzole—amyotrophic lateral sclerosis	0.00189	0.00334	CcSEcCtD
Tacrolimus—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00186	0.0033	CcSEcCtD
Tacrolimus—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00325	CcSEcCtD
Tacrolimus—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.00184	0.00325	CcSEcCtD
Tacrolimus—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00183	0.00324	CcSEcCtD
Tacrolimus—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00318	CcSEcCtD
Tacrolimus—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00316	CcSEcCtD
Tacrolimus—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00176	0.00312	CcSEcCtD
Tacrolimus—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00176	0.00311	CcSEcCtD
Tacrolimus—MTOR—brain—amyotrophic lateral sclerosis	0.00175	0.00911	CbGeAlD
Tacrolimus—Breast disorder—Riluzole—amyotrophic lateral sclerosis	0.00175	0.00309	CcSEcCtD
Tacrolimus—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00303	CcSEcCtD
Tacrolimus—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.0017	0.00302	CcSEcCtD
Tacrolimus—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00168	0.00298	CcSEcCtD
Tacrolimus—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00167	0.00296	CcSEcCtD
Tacrolimus—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00167	0.00296	CcSEcCtD
Tacrolimus—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00167	0.00296	CcSEcCtD
Tacrolimus—Pancreatitis—Riluzole—amyotrophic lateral sclerosis	0.00164	0.0029	CcSEcCtD
Tacrolimus—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00163	0.00288	CcSEcCtD
Tacrolimus—ORM1—nervous system—amyotrophic lateral sclerosis	0.00162	0.00839	CbGeAlD
Tacrolimus—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00161	0.00284	CcSEcCtD
Tacrolimus—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.00159	0.00281	CcSEcCtD
Tacrolimus—FKBP1A—brain—amyotrophic lateral sclerosis	0.00158	0.00819	CbGeAlD
Tacrolimus—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00276	CcSEcCtD
Tacrolimus—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.00156	0.00276	CcSEcCtD
Tacrolimus—ORM1—central nervous system—amyotrophic lateral sclerosis	0.00156	0.00808	CbGeAlD
Tacrolimus—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00154	0.00273	CcSEcCtD
Tacrolimus—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00152	0.0027	CcSEcCtD
Tacrolimus—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00152	0.00269	CcSEcCtD
Tacrolimus—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00151	0.00268	CcSEcCtD
Tacrolimus—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.0015	0.00265	CcSEcCtD
Tacrolimus—Infestation—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00264	CcSEcCtD
Tacrolimus—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.00149	0.00264	CcSEcCtD
Tacrolimus—Depression—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00263	CcSEcCtD
Tacrolimus—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00147	0.0026	CcSEcCtD
Tacrolimus—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00258	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Riluzole—amyotrophic lateral sclerosis	0.00146	0.00258	CcSEcCtD
Tacrolimus—Jaundice—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00257	CcSEcCtD
Tacrolimus—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00257	CcSEcCtD
Tacrolimus—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00145	0.00256	CcSEcCtD
Tacrolimus—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00143	0.00253	CcSEcCtD
Tacrolimus—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00251	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.00141	0.00249	CcSEcCtD
Tacrolimus—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00249	CcSEcCtD
Tacrolimus—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.0014	0.00247	CcSEcCtD
Tacrolimus—Agranulocytosis—Riluzole—amyotrophic lateral sclerosis	0.00139	0.00246	CcSEcCtD
Tacrolimus—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00136	0.00241	CcSEcCtD
Tacrolimus—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00238	CcSEcCtD
Tacrolimus—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00237	CcSEcCtD
Tacrolimus—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00237	CcSEcCtD
Tacrolimus—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00134	0.00237	CcSEcCtD
Tacrolimus—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00235	CcSEcCtD
Tacrolimus—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00235	CcSEcCtD
Tacrolimus—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00133	0.00235	CcSEcCtD
Tacrolimus—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00234	CcSEcCtD
Tacrolimus—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00233	CcSEcCtD
Tacrolimus—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00233	CcSEcCtD
Tacrolimus—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00131	0.00232	CcSEcCtD
Tacrolimus—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00224	CcSEcCtD
Tacrolimus—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00125	0.00221	CcSEcCtD
Tacrolimus—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.00124	0.0022	CcSEcCtD
Tacrolimus—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00215	CcSEcCtD
Tacrolimus—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.00121	0.00214	CcSEcCtD
Tacrolimus—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00213	CcSEcCtD
Tacrolimus—Chills—Riluzole—amyotrophic lateral sclerosis	0.0012	0.00212	CcSEcCtD
Tacrolimus—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00211	CcSEcCtD
Tacrolimus—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00118	0.00209	CcSEcCtD
Tacrolimus—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.00117	0.00207	CcSEcCtD
Tacrolimus—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.00116	0.00206	CcSEcCtD
Tacrolimus—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00115	0.00203	CcSEcCtD
Tacrolimus—Tension—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00202	CcSEcCtD
Tacrolimus—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00114	0.00202	CcSEcCtD
Tacrolimus—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00113	0.002	CcSEcCtD
Tacrolimus—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00113	0.00199	CcSEcCtD
Tacrolimus—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00112	0.00198	CcSEcCtD
Tacrolimus—Tremor—Riluzole—amyotrophic lateral sclerosis	0.00109	0.00193	CcSEcCtD
Tacrolimus—ALB—brain—amyotrophic lateral sclerosis	0.00108	0.00563	CbGeAlD
Tacrolimus—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00108	0.00191	CcSEcCtD
Tacrolimus—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00108	0.0019	CcSEcCtD
Tacrolimus—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00107	0.00189	CcSEcCtD
Tacrolimus—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00186	CcSEcCtD
Tacrolimus—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.00105	0.00185	CcSEcCtD
Tacrolimus—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00185	CcSEcCtD
Tacrolimus—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.00104	0.00184	CcSEcCtD
Tacrolimus—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00103	0.00182	CcSEcCtD
Tacrolimus—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00102	0.00181	CcSEcCtD
Tacrolimus—Cough—Riluzole—amyotrophic lateral sclerosis	0.00102	0.0018	CcSEcCtD
Tacrolimus—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00101	0.00179	CcSEcCtD
Tacrolimus—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.001	0.00178	CcSEcCtD
Tacrolimus—ABCB1—embryo—amyotrophic lateral sclerosis	0.000994	0.00516	CbGeAlD
Tacrolimus—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00099	0.00175	CcSEcCtD
Tacrolimus—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00099	0.00175	CcSEcCtD
Tacrolimus—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00099	0.00175	CcSEcCtD
Tacrolimus—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.000987	0.00175	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000983	0.00174	CcSEcCtD
Tacrolimus—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000978	0.00173	CcSEcCtD
Tacrolimus—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.000968	0.00172	CcSEcCtD
Tacrolimus—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.000957	0.0017	CcSEcCtD
Tacrolimus—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.000949	0.00168	CcSEcCtD
Tacrolimus—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000949	0.00168	CcSEcCtD
Tacrolimus—Infection—Riluzole—amyotrophic lateral sclerosis	0.000943	0.00167	CcSEcCtD
Tacrolimus—Shock—Riluzole—amyotrophic lateral sclerosis	0.000934	0.00165	CcSEcCtD
Tacrolimus—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000931	0.00165	CcSEcCtD
Tacrolimus—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.000929	0.00165	CcSEcCtD
Tacrolimus—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000927	0.00164	CcSEcCtD
Tacrolimus—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000922	0.00163	CcSEcCtD
Tacrolimus—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000918	0.00163	CcSEcCtD
Tacrolimus—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000905	0.0016	CcSEcCtD
Tacrolimus—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000887	0.00157	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000865	0.00153	CcSEcCtD
Tacrolimus—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000859	0.00152	CcSEcCtD
Tacrolimus—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000852	0.00151	CcSEcCtD
Tacrolimus—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000846	0.0015	CcSEcCtD
Tacrolimus—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000844	0.00149	CcSEcCtD
Tacrolimus—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.000836	0.00148	CcSEcCtD
Tacrolimus—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000825	0.00146	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.00082	0.00145	CcSEcCtD
Tacrolimus—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000818	0.00145	CcSEcCtD
Tacrolimus—Pain—Riluzole—amyotrophic lateral sclerosis	0.000812	0.00144	CcSEcCtD
Tacrolimus—Constipation—Riluzole—amyotrophic lateral sclerosis	0.000812	0.00144	CcSEcCtD
Tacrolimus—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.000782	0.00139	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000776	0.00137	CcSEcCtD
Tacrolimus—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.000754	0.00134	CcSEcCtD
Tacrolimus—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00075	0.00133	CcSEcCtD
Tacrolimus—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00075	0.00133	CcSEcCtD
Tacrolimus—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000699	0.00124	CcSEcCtD
Tacrolimus—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000681	0.00121	CcSEcCtD
Tacrolimus—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000674	0.0035	CbGeAlD
Tacrolimus—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000672	0.00119	CcSEcCtD
Tacrolimus—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00065	0.00115	CcSEcCtD
Tacrolimus—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000649	0.00337	CbGeAlD
Tacrolimus—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000635	0.0033	CbGeAlD
Tacrolimus—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000628	0.00111	CcSEcCtD
Tacrolimus—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000604	0.00107	CcSEcCtD
Tacrolimus—Rash—Riluzole—amyotrophic lateral sclerosis	0.000599	0.00106	CcSEcCtD
Tacrolimus—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000598	0.00106	CcSEcCtD
Tacrolimus—Headache—Riluzole—amyotrophic lateral sclerosis	0.000595	0.00105	CcSEcCtD
Tacrolimus—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000566	0.00294	CbGeAlD
Tacrolimus—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000564	0.000999	CcSEcCtD
Tacrolimus—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000477	0.00248	CbGeAlD
Tacrolimus—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.00046	0.00239	CbGeAlD
Tacrolimus—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000449	0.00233	CbGeAlD
Tacrolimus—ABCB1—brain—amyotrophic lateral sclerosis	0.000365	0.0019	CbGeAlD
Tacrolimus—FKBP1A—Disease—VCP—amyotrophic lateral sclerosis	0.000248	0.00102	CbGpPWpGaD
Tacrolimus—CYP3A7—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000246	0.00101	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000245	0.00101	CbGpPWpGaD
Tacrolimus—MTOR—ErbB Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.000243	0.001	CbGpPWpGaD
Tacrolimus—CYP3A7—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000243	0.001	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000241	0.000993	CbGpPWpGaD
Tacrolimus—ALB—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000241	0.000992	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—CASP9—amyotrophic lateral sclerosis	0.000237	0.000976	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000236	0.000972	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KIFAP3—amyotrophic lateral sclerosis	0.000234	0.000964	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	0.000231	0.000952	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—CD40LG—amyotrophic lateral sclerosis	0.00023	0.000947	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—CST3—amyotrophic lateral sclerosis	0.000229	0.000944	CbGpPWpGaD
Tacrolimus—MTOR—Disease—VTA1—amyotrophic lateral sclerosis	0.000228	0.000939	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—DCTN1—amyotrophic lateral sclerosis	0.000228	0.000937	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—SOD1—amyotrophic lateral sclerosis	0.000227	0.000934	CbGpPWpGaD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.000225	0.000925	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.000224	0.000923	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000224	0.000921	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—GSTP1—amyotrophic lateral sclerosis	0.000221	0.000911	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—C3—amyotrophic lateral sclerosis	0.000221	0.000908	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.00022	0.000904	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000217	0.000892	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000211	0.000868	CbGpPWpGaD
Tacrolimus—MTOR—Oncostatin M Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.00021	0.000862	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000208	0.000857	CbGpPWpGaD
Tacrolimus—ALB—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000205	0.000844	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—C3—amyotrophic lateral sclerosis	0.000203	0.000837	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—ERBB4—amyotrophic lateral sclerosis	0.000203	0.000836	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—SQSTM1—amyotrophic lateral sclerosis	0.000202	0.000833	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.0002	0.000823	CbGpPWpGaD
Tacrolimus—MTOR—AMPK Signaling—TP53—amyotrophic lateral sclerosis	0.0002	0.000822	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000195	0.000802	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000194	0.000798	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000192	0.000792	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.00019	0.000783	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.00019	0.000782	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—ATF1—amyotrophic lateral sclerosis	0.00019	0.000781	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000189	0.000777	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000189	0.000777	CbGpPWpGaD
Tacrolimus—MTOR—VEGFA-VEGFR2 Pathway—VEGFA—amyotrophic lateral sclerosis	0.000186	0.000766	CbGpPWpGaD
Tacrolimus—CYP3A4—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000185	0.000761	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000183	0.000754	CbGpPWpGaD
Tacrolimus—ALB—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000183	0.000752	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000183	0.000751	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CASP9—amyotrophic lateral sclerosis	0.000181	0.000744	CbGpPWpGaD
Tacrolimus—CYP3A5—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000178	0.000733	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CST3—amyotrophic lateral sclerosis	0.000178	0.000732	CbGpPWpGaD
Tacrolimus—ALB—Platelet degranulation—IGF1—amyotrophic lateral sclerosis	0.000177	0.000727	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by VEGF—VEGFA—amyotrophic lateral sclerosis	0.000176	0.000723	CbGpPWpGaD
Tacrolimus—CYP3A5—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000176	0.000723	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000174	0.000714	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CHMP2B—amyotrophic lateral sclerosis	0.000173	0.000712	CbGpPWpGaD
Tacrolimus—MTOR—BDNF signaling pathway—CASP3—amyotrophic lateral sclerosis	0.000173	0.000712	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000173	0.00071	CbGpPWpGaD
Tacrolimus—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—amyotrophic lateral sclerosis	0.000168	0.000693	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000168	0.000692	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—CASP9—amyotrophic lateral sclerosis	0.000167	0.000687	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000167	0.000685	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—CASP3—amyotrophic lateral sclerosis	0.000166	0.000685	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—MMP9—amyotrophic lateral sclerosis	0.000166	0.000684	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.00016	0.00066	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000159	0.000655	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000157	0.000647	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PLB1—amyotrophic lateral sclerosis	0.000156	0.000644	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—ERBB4—amyotrophic lateral sclerosis	0.000155	0.000637	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.000152	0.000626	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000151	0.000621	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000149	0.000614	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000148	0.000607	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD40LG—amyotrophic lateral sclerosis	0.000145	0.000598	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	0.000145	0.000595	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—ERBB4—amyotrophic lateral sclerosis	0.000143	0.000588	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—TP53—amyotrophic lateral sclerosis	0.000143	0.000588	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—ATF1—amyotrophic lateral sclerosis	0.000142	0.000585	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.000141	0.000582	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	0.000141	0.000582	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000141	0.000581	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000141	0.000579	CbGpPWpGaD
Tacrolimus—MTOR—Disease—VCP—amyotrophic lateral sclerosis	0.000139	0.000574	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—DCTN1—amyotrophic lateral sclerosis	0.000138	0.000568	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.000137	0.000564	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—DAO—amyotrophic lateral sclerosis	0.000136	0.000561	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000136	0.000561	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000136	0.000561	CbGpPWpGaD
Tacrolimus—ALB—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	0.000136	0.000559	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CASP9—amyotrophic lateral sclerosis	0.000135	0.000557	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000131	0.000538	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CASP9—amyotrophic lateral sclerosis	0.00013	0.000535	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CASP9—amyotrophic lateral sclerosis	0.000129	0.000532	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	0.000129	0.000529	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—C3—amyotrophic lateral sclerosis	0.000128	0.000529	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000125	0.000513	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000123	0.000505	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000122	0.000504	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	0.00012	0.000495	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000119	0.000489	CbGpPWpGaD
Tacrolimus—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	0.000118	0.000485	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000117	0.000483	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000117	0.000483	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000117	0.000481	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000116	0.000477	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—ERBB4—amyotrophic lateral sclerosis	0.000116	0.000477	CbGpPWpGaD
Tacrolimus—ALB—Platelet degranulation—VEGFA—amyotrophic lateral sclerosis	0.000115	0.000475	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	0.000115	0.000474	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000113	0.000467	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—ERBB4—amyotrophic lateral sclerosis	0.000111	0.000458	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—ERBB4—amyotrophic lateral sclerosis	0.000111	0.000456	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—APOE—amyotrophic lateral sclerosis	0.00011	0.000455	CbGpPWpGaD
Tacrolimus—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—amyotrophic lateral sclerosis	0.00011	0.000453	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.00011	0.000451	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	0.00011	0.000451	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000109	0.000449	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000107	0.000442	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000107	0.000442	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—amyotrophic lateral sclerosis	0.000107	0.000439	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD40LG—amyotrophic lateral sclerosis	0.000105	0.00043	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000104	0.000429	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000104	0.000429	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000103	0.000426	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000103	0.000424	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000103	0.000424	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000103	0.000424	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	0.000102	0.00042	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—TP53—amyotrophic lateral sclerosis	0.000102	0.000419	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000101	0.000417	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CST3—amyotrophic lateral sclerosis	0.0001	0.000412	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.0001	0.000412	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	9.99e-05	0.000411	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—SACM1L—amyotrophic lateral sclerosis	9.99e-05	0.000411	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—DAO—amyotrophic lateral sclerosis	9.86e-05	0.000406	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—VCP—amyotrophic lateral sclerosis	9.76e-05	0.000402	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—C3—amyotrophic lateral sclerosis	9.62e-05	0.000396	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GSR—amyotrophic lateral sclerosis	9.54e-05	0.000393	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	9.51e-05	0.000391	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	9.45e-05	0.000389	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	9.41e-05	0.000387	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	9.4e-05	0.000387	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—FIG4—amyotrophic lateral sclerosis	9.39e-05	0.000387	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	9.28e-05	0.000382	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—C3—amyotrophic lateral sclerosis	9.24e-05	0.00038	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	9.12e-05	0.000376	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	9.12e-05	0.000376	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	9.06e-05	0.000373	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—VEGFA—amyotrophic lateral sclerosis	9.04e-05	0.000372	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—SQSTM1—amyotrophic lateral sclerosis	8.82e-05	0.000363	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	8.75e-05	0.00036	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—APOE—amyotrophic lateral sclerosis	8.56e-05	0.000353	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—DAO—amyotrophic lateral sclerosis	8.49e-05	0.00035	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	8.39e-05	0.000346	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—C3—amyotrophic lateral sclerosis	8.31e-05	0.000342	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	8.3e-05	0.000342	CbGpPWpGaD
Tacrolimus—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	8.27e-05	0.000341	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ATF1—amyotrophic lateral sclerosis	8.27e-05	0.000341	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	8.23e-05	0.000339	CbGpPWpGaD
Tacrolimus—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	8.16e-05	0.000336	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	8.13e-05	0.000335	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CASP9—amyotrophic lateral sclerosis	7.88e-05	0.000324	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	7.84e-05	0.000323	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CHAT—amyotrophic lateral sclerosis	7.83e-05	0.000322	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	7.75e-05	0.000319	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—APOE—amyotrophic lateral sclerosis	7.73e-05	0.000318	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	7.72e-05	0.000318	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—PTGS2—amyotrophic lateral sclerosis	7.57e-05	0.000312	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	7.47e-05	0.000308	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	7.44e-05	0.000306	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	7.29e-05	0.0003	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CASP9—amyotrophic lateral sclerosis	7.27e-05	0.000299	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	6.9e-05	0.000284	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—TP53—amyotrophic lateral sclerosis	6.83e-05	0.000281	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—ERBB4—amyotrophic lateral sclerosis	6.74e-05	0.000278	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—SOD1—amyotrophic lateral sclerosis	6.62e-05	0.000273	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—C3—amyotrophic lateral sclerosis	6.44e-05	0.000265	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PLB1—amyotrophic lateral sclerosis	6.44e-05	0.000265	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	6.4e-05	0.000263	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	6.39e-05	0.000263	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	6.34e-05	0.000261	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	6.34e-05	0.000261	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD40LG—amyotrophic lateral sclerosis	6.34e-05	0.000261	CbGpPWpGaD
Tacrolimus—MTOR—Disease—ERBB4—amyotrophic lateral sclerosis	6.23e-05	0.000256	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	6e-05	0.000247	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	5.94e-05	0.000245	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	5.94e-05	0.000244	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSR—amyotrophic lateral sclerosis	5.94e-05	0.000244	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PTGS2—amyotrophic lateral sclerosis	5.87e-05	0.000242	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	5.8e-05	0.000239	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	5.7e-05	0.000235	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	5.66e-05	0.000233	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	5.64e-05	0.000232	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—C3—amyotrophic lateral sclerosis	5.6e-05	0.000231	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	5.41e-05	0.000223	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.39e-05	0.000222	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	5.35e-05	0.00022	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	5.2e-05	0.000214	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	5.12e-05	0.000211	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	5.09e-05	0.00021	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	5.07e-05	0.000209	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	5.04e-05	0.000207	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.96e-05	0.000204	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	4.92e-05	0.000202	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CHAT—amyotrophic lateral sclerosis	4.88e-05	0.000201	CbGpPWpGaD
Tacrolimus—MTOR—Disease—APOE—amyotrophic lateral sclerosis	4.82e-05	0.000198	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	4.65e-05	0.000191	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	4.58e-05	0.000189	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.45e-05	0.000183	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	4.36e-05	0.000179	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	4.27e-05	0.000176	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.21e-05	0.000173	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.17e-05	0.000172	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	4.1e-05	0.000169	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IGF1—amyotrophic lateral sclerosis	4.04e-05	0.000166	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.87e-05	0.000159	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.81e-05	0.000157	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	3.81e-05	0.000157	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.62e-05	0.000149	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.6e-05	0.000148	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	3.47e-05	0.000143	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—APOE—amyotrophic lateral sclerosis	3.37e-05	0.000139	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTGS2—amyotrophic lateral sclerosis	3.3e-05	0.000136	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	3.24e-05	0.000133	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	3.21e-05	0.000132	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—APOE—amyotrophic lateral sclerosis	3.18e-05	0.000131	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.15e-05	0.00013	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.05e-05	0.000126	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.04e-05	0.000125	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.8e-05	0.000115	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.79e-05	0.000115	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—VEGFA—amyotrophic lateral sclerosis	2.64e-05	0.000109	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	2.63e-05	0.000108	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.62e-05	0.000108	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.45e-05	0.000101	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.41e-05	9.92e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	2.3e-05	9.47e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.3e-05	9.45e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.18e-05	8.98e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	2.15e-05	8.83e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.11e-05	8.69e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	2.03e-05	8.35e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—amyotrophic lateral sclerosis	1.99e-05	8.21e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—APOE—amyotrophic lateral sclerosis	1.98e-05	8.16e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.82e-05	7.49e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	1.74e-05	7.15e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.58e-05	6.49e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.42e-05	5.82e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.38e-05	5.66e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.36e-05	5.59e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.3e-05	5.35e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.19e-05	4.9e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	1.07e-05	4.4e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.33e-06	3.02e-05	CbGpPWpGaD
